Latest Breaking News On - Product finance - Page 3 : comparemela.com

Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treat

Search jobs 01-Jun-2021 Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis - NDA supported by positive data from VIOLET and ultraVIOLET Phase 3 clinical trials evaluating oteseconazole in more than 870 women in 11 countries - - Oteseconazole’s Qualified Infectious Disease Product and Fast-Track designations allow for six-month priority review by FDA following its acceptance of the NDA - DURHAM, N.C. (BUSINESS WIRE) Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced it has submitted its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC). Also known as chronic yeast infection, RVVC is a debilitating inf

NovaQuest Capital Management: Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development

(0) Argenta Limited ( Argenta ), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management ( NovaQuest ) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005132/en/ The collaboration leverages NovaQuest s capital and expertise, and Argenta s knowledge and know-how in research and development activities that advance animal health. The capital investment from NovaQuest accelerates Argenta s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strengthening our partnership through additional programs in the future, said Ben Russell, CEO of Arge

Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development

Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development on May 20 2021 8:30 PM RALEIGH, N.C. & AUCKLAND, New Zealand (BUSINESS WIRE) Argenta Limited (“Argenta”), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management (“NovaQuest”) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals. The collaboration leverages NovaQuest’s capital and expertise, and Argenta’s knowledge and know-how in research and development activities that advance animal health. “The capital investment from NovaQuest accelerates Argenta’s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strengthening our partn

Aceragen Launches with Acquisition of Enzyvant's Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest

Published: May 03, 2021 Acquires worldwide rights to RVT-801, a novel enzyme replacement therapy for treatment of Farber disease NovaQuest investment to fund product and clinical development Protocol for potential single registration study reviewed with FDA and EMA Program has been granted rare pediatric disease status, fast track and orphan designations, and is eligible for a priority review voucher once approved RESEARCH TRIANGLE PARK, N.C. & BASEL, Switzerland (BUSINESS WIRE) Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and ultra-rare diseases, today announced the acquisition of Enzyvant’s RVT-801 (now ACG-801), an investigational enzyme replacement therapy (ERT) for acid ceramidase deficiency presenting as Farber disease, a lysosomal storage disease with a unique, severe inflammatory phenotype for which no disease-specific therapy exists. Enzyvant will receive an upfront payment and development and sales-ba

మళ్ళీ పడగ విప్పుతున్న ద్రవ్యోల్బణం